ÂÜÀòÂÒÂ×

Douglas Lind joined Biomark Capital in November 2013. Previously he served as Managing Director at Burrill & Company and GBP Capital, a Greenwich, Connecticut-based healthcare venture firm. He has more than 20 years of experience in the life sciences industry, ranging from the practice of clinical medicine to working as a top-tier Wall Street equity research analyst and venture capitalist. Throughout his career, he has focused on identifying promising disruptive technologies and visionary leadership that offer high-value solutions to pressing medical needs. He served as a senior biotechnology equity research analyst at Morgan Stanley from 1997 through 2002 and at PaineWebber from 1995 to 1997. His coverage of large and small capitalization biotechnology companies included Amgen, Biogen, Celera (acquired by Quest Diagnostics), Centocor (acquired by Johnson & Johnson), Chiron (acquired by Novartis), IDEC Pharmaceuticals (acquired by Biogen), ImClone (acquired by Bristol-Myers Squibb), MedImmune (acquired by AstraZeneca), Agouron (acquired by Warner-Lambert), Axys Pharmaceuticals (acquired by Celera) and Millenium Pharmaceuticals (acquired by Takeda Pharmaceuticals).

Dr. Lind is a graduate of the University of Iowa College of Medicine. He served as an attending physician at St. Elizabeth's Hospital in Boston, a major teaching affiliate of Tufts University School of Medicine, where he completed residency training in internal medicine. He currently serves on the board of directors of Lentigen and HyperMed Imaging.